Pliant Therapeutics Appoints New Chief Medical Officer

TL;DR

Pliant Therapeutics just hired a new CMO from Gilead. Big move for their drug pipeline.

AI Summary

Pliant Therapeutics, Inc. announced on June 13, 2024, the appointment of Dr. David J. E. Mann as Chief Medical Officer. Dr. Mann previously served as Senior Vice President and Head of Clinical Development at Gilead Sciences. This appointment is part of the company's ongoing efforts to advance its clinical pipeline.

Why It Matters

The appointment of a new Chief Medical Officer with extensive experience from a major biopharmaceutical company like Gilead Sciences could signal a strategic shift or acceleration in Pliant Therapeutics' drug development programs.

Risk Assessment

Risk Level: medium — The appointment of a new executive can introduce uncertainty regarding strategic direction and pipeline execution, though the individual's background may mitigate some risk.

Key Players & Entities

• Pliant Therapeutics, Inc. (company) — Registrant
• Dr. David J. E. Mann (person) — Appointed Chief Medical Officer
• Gilead Sciences (company) — Dr. Mann's previous employer
• June 13, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share PLRX The Nasdaq Stock Market
• $40,000 — gnes will receive an annual retainer of $40,000 starting on the Effective Date, with pa
• $17,000 — gnes will receive an annual retainer of $17,000 for his service as Chairperson of the A

Filing Documents

• plrx-20240613.htm (8-K) — 40KB
• 0001746473-24-000084.txt ( ) — 162KB
• plrx-20240613.xsd (EX-101.SCH) — 2KB
• plrx-20240613_lab.xml (EX-101.LAB) — 21KB
• plrx-20240613_pre.xml (EX-101.PRE) — 12KB
• plrx-20240613_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. The Company held its Annual Meeting of Stockholders (the "Annual Meeting") on June 13, 2024. As of April 19, 2024, the record date for the Annual Meeting, there were 60,318,732 shares of the Company's common stock outstanding and entitled to vote at the Annual Meeting. The Company's stockholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 22, 2024: (i) to elect Hoyoung Huh, M.D., Ph.D., Darren Cline, MBA, and David Pyott, MA, MBA, as Class I directors of the Company to serve for a three-year term ending at the Annual Meeting of Stockholders to be held in 2027 ("Proposal 1"), (ii) to approve, by non-binding advisory vote, the resolution approving the compensation of the Company's named executive officers ("Proposal 2") and (iii) to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2024 ("Proposal 3"). Proposal 1: The Company's stockholders approved the election of the aforementioned Class I directors recommended for election at the Annual Meeting. The Company's stockholders voted for the Class I directors as follows: Nominee For Withhold Hoyoung Huh, M.D., Ph.D. 39,087,800 12,731,485 Darren Cline, MBA 51,397,449 421,836 David Pyott, MA, MBA 48,388,729 3,430,556 The broker non-votes for Proposal 1 totaled 4,882,934 shares of common stock. Proposal 2: The Company's stockholders failed to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers. The proposal required a majority of the votes cast for approval, and were as follows: For Against Abstain 23,479,353 28,329,655 10,277 The broker non-votes for Proposal 2 totaled 4,882,934 shares of common stock. Proposal 3: The Company's stockholders ratified the selection of Deloi

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. PLIANT THERAPEUTICS, INC. Date: June 14 , 2024 By: /s/ Keith Cummings Keith Cummings, M.D., MBA Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR